TerlipressinHospital peptide medicine
Terlipressin is used in a hospital setting where severe liver disease has disrupted circulation and kidney function. Its potential benefit comes with important respiratory and vascular risks.
What is Terlipressin?
Terlipressin is a vasopressin analogue used in specialised hospital care, including hepatorenal syndrome associated with advanced liver disease.
How it works
Vasoconstriction in the abdominal circulation alters the circulatory disturbance involved in hepatorenal syndrome.
Effects studied
What does the evidence show?
Hepatorenal syndrome trial and product safety information
The connection between liver and kidney
In advanced liver disease, major changes in circulation can leave the kidneys underperfused even when kidney tissue is not the initial problem. Terlipressin is a vasopressin analogue that constricts blood vessels, including those in the abdominal circulation, to alter this distribution.
What treatment is trying to achieve
Treatment aims to restore kidney function in a person with hepatorenal syndrome, an urgent and complex illness that often raises the question of liver transplantation. A better creatinine result can matter, but does not by itself establish a survival advantage.
A particularly important risk
The US prescribing information carries a warning about serious or fatal respiratory failure. Fluid overload and impaired oxygenation are central concerns. Reduced blood supply to other tissues is another risk, which explains why monitoring involves more than the kidney laboratory results alone. 1
Why setting matters
Terlipressin requires close hospital assessment of circulation, oxygenation, fluid balance and the underlying liver disease. Constricting vessels can help one organ while harming another. Its role therefore depends on the diagnosis and the patient’s overall condition; the broad claim that it “improves kidney function” leaves out essential context.
Safety & status
The US label warns of serious or fatal respiratory failure. Oxygen status, fluid overload and ischaemia are central safety considerations. 1
Country and product status
The US Terlivaz label addresses adults with hepatorenal syndrome with rapid reduction in kidney function; other jurisdictions and indications differ.
Frequently asked questions
Is it a general treatment for chronic kidney disease?
No. The setting described here is kidney dysfunction associated with advanced liver disease.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- DailyMed · Terlivaz prescribing information US prescribing information · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
- Terlipressin · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Terlipressin · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.